tirzepatide cardiovascular outcomes study Matches Dulaglutide in Large CV Trial: SURPASS-CVOT In patients with type 2

While Tirzepatide offers a promising solution for managing type 2 diabetes and aiding in weight loss, it is essential for patients to be well-informed about its potential side effects and interactions

It is a small-molecule oral GLP-1 receptor agonist developed by Eli Lilly, the same company behind tirzepatide

World Health Organization

From FDA approval criteria and clinical trial enrollment standards to the wildly inconsistent rules insurance companies use to approve or reject coverage, this guide covers the full picture

Smaller ones aren't supposed to make products that are essentially copies of a commercially available drug, a moniker with some wiggle room